Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, produced large weight reductions in a phase 2 trial. It remains investigational; 'research' products sold online are not the trial drug and their contents are unverified.
Key points
- A 48-week phase 2 trial reported mean weight reductions exceeding 20% at the highest doses.
- Gastrointestinal adverse events were common and dose-related.
- Heart-rate increases were observed.
- Products sold online under this name have not been independently verified; label identity and concentration cannot be assumed.
What the literature shows
Jastreboff and colleagues reported dose-dependent weight loss in adults with obesity in a randomised, placebo-controlled phase 2 trial.
A parallel phase 2 trial in type 2 diabetes reported improvements in glycaemic control and weight.
What remains unknown
- Phase 3 outcome and long-term safety data are still emerging.
- Lean-mass loss proportion and implications for active people.
Safety and monitoring implications
- Nausea, vomiting and dehydration can be significant; severe abdominal pain warrants assessment for pancreatitis or gallbladder disease.
- Grey-market peptides carry identity, contamination and sterility risks.
Cited literature
- 1.Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. Find on PubMed
- 2.Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. Find on PubMed
Community reports
Anecdotal — not scientific evidence
Lived experience is valuable context and often surfaces problems before the literature does. It is also uncontrolled, unverified and subject to bias, so it never overrides published findings here.
Editorial evidence status
MixedCommunity discussion of this compound is widespread, but no independently verified reports were available for this analysis. Anecdotes have not been invented or treated as clinical evidence.
Buying Retatrutide in Australia: what to check first
APEDRA does not sell Retatrutide or any other product, and takes no commission from suppliers. If you are researching where to buy it, the biggest practical risk is not the compound itself but what is actually in the bottle: under-dosing, substitution with a different compound, and contamination are all documented in independent testing of online research chemicals.
- Ask for a batch-specific third-party lab report (HPLC/mass spectrometry), not a generic certificate.
- Check independent review platforms, not only reviews hosted on the seller's own site.
- Read the shipping, returns and refund policies before ordering.
- Be wary of prices far below the market or exaggerated results claims.
Compare Australian vendors independently · how we assess suppliers
Terms used here are defined in our glossary, and the evidence-grading scale explains what this analysis's grade means. If you believe something here is wrong, tell us.
This analysis is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.